Antifibrotic Activity Of GI262570 In Chronic Hepatitis C Subjects



Status:Completed
Conditions:Gastrointestinal, Hepatitis, Hepatitis, Hepatitis
Therapuetic Areas:Gastroenterology, Immunology / Infectious Diseases
Healthy:No
Age Range:40 - 70
Updated:12/13/2017
Start Date:November 2, 2005
End Date:March 13, 2008

Use our guide to learn which trials are right for you!

A Double-Blind, Randomized, Placebo-Controlled Multi-Center, Phase II Parallel Dose-Ranging Study to Assess the Antifibrotic Activity of GI262570 in Chronic Hepatitis C Subjects With Hepatic Fibrosis Who Have Failed Prior Antiviral Therapy

The purpose of this study is to examine the safety and effectiveness of GI262570 compared to
placebo (a pill that looks exactly like GI262570 but contains no active medicine) in
improving specific tests that indicate the degree of liver fibrosis (scarring). Subjects who
are enrolled in the study must have had prior treatment with interferon (either pegylated or
standard interferon) plus ribavirin for at least 12 weeks to treat their hepatitis C, but
either failed to clear the virus or didn't tolerate the treatment.


Inclusion criteria:

- A subject will be eligible for inclusion in this study only if all of the following
criteria apply:

- Age between 40 and 70 years, inclusive.

- Documented positive serology for HCV antibody by a second generation or higher assay.

- Serum HCV RNA positive and HCV viral Genotype 1 at pre-screening visit.

- Ishak fibrosis score of 2, 3 or 4.

- Failure to achieve sustained virologic response (SVR) with previous interferon
(standard or pegylated) and ribavirin treatment administered at a minimum dose of 3mU
three times weekly or equivalent, for at least 12 weeks. Reasons for failure may
include failure to respond to treatment or intolerability to optimal treatment. Prior
treatment with interferon/ribavirin must have been discontinued at least 11 months
prior to the biopsy date.

- Male or female; a female is eligible to enter and participate in this study if she is
of:

1. non-childbearing potential (i.e., physiologically incapable of becoming pregnant,
including any female who is post-menopausal); or,

2. child-bearing potential, has a negative serum pregnancy test at screen, and
agrees to one of the following:

- Complete abstinence from intercourse from 2 weeks prior to administration of
the study drug, throughout the study, and for a time interval after
completion or premature discontinuation from the study to account for
elimination of the investigational drug, (a minimum of 5 half-lives or
longer if the pharmacodynamic profile of the investigational drug warrants a
longer time period); or,

- Female sterilization; or,

- Has a male partner who is sterilized; or,

- Implants of levonorgestrel; or,

- Injectable progestogen; or,

- Oral contraceptive (combined or progestogen only) , must be stable for 3
months prior to study entry; or,

- Any intrauterine device (IUD) with published data showing that the lowest
expected failure rate is less than 1% per year (not all IUDs meet this
criterion); or,

- Any other methods with published data showing that the lowest expected
failure rate for that method is less than 1% per year; or,

- Barrier method only if used in combination with any of the above acceptable
methods.

- Availability and willingness of subject to provide written informed consent.

Exclusion criteria:

A subject will not be eligible for inclusion in this study if any of the following criteria
apply:

- History of ascites, variceal hemorrhage, hepatic encephalopathy, spontaneous bacterial
peritonitis or other signs of hepatic decompensation.

- Current or historical evidence suggestive of ischemic heart disease or other
cardiovascular disease that in the investigator's opinion may adversely impact the
safety of the subject during the conduct of the study. Evidence suggestive of
cardiovascular disease may come from a number of sources, including clinical history,
physical exam, electrocardiogram, laboratory testing, and radiographic procedures.

- New York Heart Association (NYHA) Functional Class 1, 2, 3, or 4 cardiac status

- Co-infection with HBV or HIV.

- Liver histology consistent with any other co-existing cause of chronic liver disease.

- Documented evidence of a hepatic mass lesion suspicious for hepatocellular carcinoma.

- Alpha-fetoprotein > 200ng/mL at pre-screening.

- Inadequate hematologic function defined by any of the following:

Hemoglobin (<12.5 g/dL for men)(<12.0 g/dL for women)

Absolute Neutrophil Count (ANC) (<1.0 x 10^9/L) Platelets (<130X/10^9/L)

- Inadequate renal function defined as:

Serum creatinine (>1.5mg/dL (≥130mmol/L)) Calculated creatinine clearance as calculated by
Cockcroft and Gault (<60mL/min)

- Serum ALT level ≥5 x ULN.

- Albumin <3.2g/dL.

- Total bilirubin >1.2 x ULN.

- Prothrombin time > 15 seconds or International normalized ratio (INR) > 1.3.

- Organ, stem cell, or bone marrow transplant.

- Serious concurrent medical illness that in the investigator's opinion might interfere
with therapy. This includes significant systemic illnesses (other than liver disease)
such as chronic pancreatitis.

- Active systemic autoimmune disorder.

- A pre-existing condition interfering with normal gastrointestinal anatomy or motility,
and/or renal function that could interfere with the absorption, metabolism, and/or
excretion of the study drugs.

- Other medical conditions that, in the investigator's opinion, might interfere with
compliance with therapy, participation in the study or interpretation of results.

- Pregnancy (or lactation) or, in subjects capable of bearing children,
inability/unwillingness to practice adequate contraception.

- Females of child-bearing potential (post-puberty) unwilling or unable to have
pregnancy testing at any study visit.

- Therapy with systemic cytotoxic agents, immunomodulators, or immunosuppressive therapy
requiring use of more than 5mg of prednisone (or its equivalent) per day.

- Therapy with a systemic antiviral agent (with the exception of prophylaxis or
treatment of influenza or chronic HSV) within the past 30 days.

- Concurrent participation in another clinical trial in which the subject is or will be
exposed to another investigational or a non-investigational drug or device within 30
days of the screening visit.

- Current therapy or anticipated need for therapy with hypoglycemic drugs (e.g.,
insulin, sulfonylurea or metformin).

- Known hypersensitivity to GI262570, or to any component of the GI262570 soft gelatin
capsules, dispersion tablets or the sodium salt tablet or to PPARg agonists.

- A history of hepatotoxicity to TZDs and/or a history of severe edema or medically
serious fluid-related events associated with the use of TZDs.

- Use of other PPAR agonists (e.g., rosiglitazone, pioglitazone) within 1 year from the
start of dosing.

- Active alcohol abuse within the past 1 year.

- Use of illegal drugs in the past 1 year. 30a. Macular edema or history of macular
edema.
We found this trial at
49
sites
Indianapolis, Indiana 46202
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Ann Arbor, Michigan 48109
1934
mi
from 91732
Ann Arbor, MI
Click here to add this to my saved trials
Atlanta, Georgia 30341
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Bakersfield, California 93309
106
mi
from 91732
Bakersfield, CA
Click here to add this to my saved trials
Binghamton, New York 13901
2330
mi
from 91732
Binghamton, NY
Click here to add this to my saved trials
Birmingham, Alabama 35249
1777
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Boston, Massachusetts 02115
2578
mi
from 91732
Boston, MA
Click here to add this to my saved trials
Chapel Hill, North Carolina 27599
2194
mi
from 91732
Chapel Hill, NC
Click here to add this to my saved trials
Charlottesville, Virginia 22903
2208
mi
from 91732
Charlottesville, VA
Click here to add this to my saved trials
Cincinnati, Ohio 45229
1880
mi
from 91732
Cincinnati, OH
Click here to add this to my saved trials
Cleveland, Ohio 44195
2036
mi
from 91732
Cleveland, OH
Click here to add this to my saved trials
Dallas, Texas 75230
1223
mi
from 91732
Dallas, TX
Click here to add this to my saved trials
Detroit, Michigan 48202
1965
mi
from 91732
Detroit, MI
Click here to add this to my saved trials
Durham, North Carolina 27705
2198
mi
from 91732
Durham, NC
Click here to add this to my saved trials
Englewood, Colorado 80110
815
mi
from 91732
Englewood, CO
Click here to add this to my saved trials
Fairfax, Virginia 22031
2267
mi
from 91732
Fairfax, VA
Click here to add this to my saved trials
Fort Lauderdale, Florida 33308
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials
Hershey, Pennsylvania 17033
2295
mi
from 91732
Hershey, PA
Click here to add this to my saved trials
Herston, Queensland
?
mi
from 91732
Herston,
Click here to add this to my saved trials
Honolulu, Hawaii 96813
2572
mi
from 91732
Honolulu, HI
Click here to add this to my saved trials
Houston, Texas 77030
1357
mi
from 91732
Houston, TX
Click here to add this to my saved trials
Iowa City, Iowa 52242
1528
mi
from 91732
Iowa City, IA
Click here to add this to my saved trials
La Jolla, California 92093
93
mi
from 91732
La Jolla, CA
Click here to add this to my saved trials
Lancaster, Pennsylvania 17605
2317
mi
from 91732
Lancaster, PA
Click here to add this to my saved trials
Los Angeles, California 90025
24
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Louisville, Kentucky 40202
1813
mi
from 91732
Louisville, KY
Click here to add this to my saved trials
Lutherville-Timonium, Maryland 21093
2301
mi
from 91732
Lutherville-Timonium, MD
Click here to add this to my saved trials
Manhasset, New York 11030
2448
mi
from 91732
Manhasset, NY
Click here to add this to my saved trials
Marietta, Georgia 30060
1908
mi
from 91732
Marietta, GA
Click here to add this to my saved trials
Miami, Florida 33136
2321
mi
from 91732
Miami, FL
Click here to add this to my saved trials
New York, New York 10032
2435
mi
from 91732
New York, NY
Click here to add this to my saved trials
Newport Beach, California 92663
31
mi
from 91732
Newport Beach, CA
Click here to add this to my saved trials
North Little Rock, Arkansas 72117
1464
mi
from 91732
North Little Rock, AR
Click here to add this to my saved trials
Orlando, Florida 32806
2186
mi
from 91732
Orlando, FL
Click here to add this to my saved trials
Pasadena, California 91105
9
mi
from 91732
Pasadena, CA
Click here to add this to my saved trials
Richmond, Virginia 23298
2269
mi
from 91732
Richmond, VA
Click here to add this to my saved trials
Sacramento, California 95815
365
mi
from 91732
Sacramento, CA
Click here to add this to my saved trials
Saint Louis, Missouri 63110
1570
mi
from 91732
Saint Louis, MO
Click here to add this to my saved trials
San Antonio, Texas 78258
1184
mi
from 91732
San Antonio, TX
Click here to add this to my saved trials
San Clemente, California 92673
50
mi
from 91732
San Clemente, CA
Click here to add this to my saved trials
San Francisco, California 94115
356
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Santa Clara, California 95051
317
mi
from 91732
Santa Clara, CA
Click here to add this to my saved trials
Sarasota, Florida 34232
2151
mi
from 91732
Sarasota, FL
Click here to add this to my saved trials
Syracuse, New York 13210
2320
mi
from 91732
Syracuse, NY
Click here to add this to my saved trials
The Bronx, New York 10457
?
mi
from 91732
The Bronx, NY
Click here to add this to my saved trials
Tucson, Arizona 85724
427
mi
from 91732
Tucson, AZ
Click here to add this to my saved trials
Tulsa, Oklahoma 74105
1251
mi
from 91732
Tulsa, OK
Click here to add this to my saved trials
Washington, District of Columbia 20007
2281
mi
from 91732
Washington,
Click here to add this to my saved trials
Worcester, Massachusetts 01655
2542
mi
from 91732
Worcester, MA
Click here to add this to my saved trials